Signing on an Option Agreement with Aerie Pharmaceuticals Inc., to License for Further Development of a Sub-Conjunctival Drug Implant

BioLight Ltd. entered into an option agreement with Aerie Pharmaceuticals Inc., to license the Eye-DTM technology for further development of a sub-conjunctival drug implant for the controlled release of ophthalmic medications.

Link to the complete article

Link to Newsroom

Comments are closed